Federal Health Agencies Launch Psychedelic Research Partnership
In a coordinated move announced on Monday, the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) unveiled a memorandum of understanding (MOU) designed to accelerate research and development of psychedelic medicines for serious mental health conditions. The partnership builds on an executive order issued earlier by President Donald Trump that sought to expand and expedite scientific investigation into the therapeutic potential of substances such as psilocybin, MDMA, and ibogaine.
Details of the HHS‑VA Memorandum of Understanding
The five‑year agreement outlines several concrete actions:
- Increasing veteran participation in clinical trials of rapid‑acting mental‑health treatments.
- Training therapists, nurses, physicians, and other clinicians to safely administer future FDA‑approved psychedelic drug products.
- Collecting and sharing real‑world data on safety, effectiveness, and costs to improve patient care and inform policy.
- Coordinating research and sharing evidence, consistent with legal authority, to help shape future FDA regulatory decisions and coverage policies.
- Developing clinical guidance and educational resources so providers and patients understand how approved therapies should be delivered safely and effectively.
HHS Secretary Robert F. Kennedy, Jr. emphasized the moral imperative behind the effort: “America owes every veteran the best care our nation can provide… Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA‑approved innovations and transition them from research into care so veterans can access the treatments they deserve.” VA Secretary Doug Collins echoed this sentiment, noting that the MOU ensures effective cooperation as the agencies work to turn research into life‑changing treatment.
Complementary FDA‑VA Agreement
Also announced Monday, a second MOU between the VA and the Food and Drug Administration (FDA) focuses on information sharing and scientific collaboration to advance psychedelic medicine development. FDA Acting Commissioner Kyle Diamantas stated that the agreement will allow the agency to better leverage clinical trial data, real‑world evidence, and scientific expertise while maintaining rigorous safety and effectiveness standards.
Funding for Ibogaine Research
The National Institute on Drug Abuse (NIDA) awarded $2.3 million to support an investigational new drug application for ibogaine, a compound under study for its potential to interrupt addiction cycles. NIH Director Jay Bhattacharya noted preliminary evidence that psychedelic therapies can “rewire the brain and produce rapid improvements” for individuals with serious mental illness or substance use disorders, while acknowledging the need to understand long‑term benefits and risks.
In parallel, the HHS Advanced Research Projects Agency for Health (ARPA‑H) is allocating separate funds to explore ibogaine’s role in treating opioid use disorder. ARPA‑H Director Alicia Jackson described the initiative as a bold effort to knock down barriers that have kept opioid treatment innovation stagnant for decades.
Guidance and Public Engagement
The FDA also released finalized guidance to help researchers navigate the unique challenges of studying psychedelic therapeutics. Accompanying the guidance, the agency announced a public hearing scheduled for September to gather stakeholder input on psychedelic therapy issues. The tweet below captures the FDA’s announcement:
FDA is taking new steps to support the development of potential psychedelic drug therapies for serious mental health conditions. Today, FDA, issued final guidance for industry on clinical investigations of psychedelic drugs, announced a public hearing to gather stakeholder input… pic.twitter.com/Y102CzYiOi
— U.S. FDA (@US_FDA) July 13, 2026
Legislative Context
These federal actions follow a series of congressional initiatives aimed at bolstering psychedelic research. In April, HHS and the FDA announced steps to accelerate therapeutic access to psychedelics for patients with serious mental health conditions. A bipartisan coalition of 32 members of Congress urged the FDA in May to expedite ongoing reviews of psychedelic therapies. More recently, lawmakers introduced a bill requiring the Department of Defense to evaluate how psilocybin research could benefit service members, and another measure seeks to codify Trump’s psychedelics executive order into law. A pending amendment to the National Defense Authorization Act would extend the DOD’s psychedelic research effort for an additional six years.
For the original reporting and additional details, see the source: Here
